ClinicalTrials.govpublic full text
Phase 1/2A Study of TRC253, an Androgen Receptor Antagonist, in Metastatic Castration-resistant Prostate Cancer Patients
metastatic castrate-resistant prostate cancer, adenocarcinoma, prostate, interventional, phase1, phase2
This document is indexed with metadata only — full text is not available in the archive for this record.
Open the official source ↗
Related documents
Record · ID 801228
Retrieved via
Conceptio — every document is proof-bundled with source, license, and retrieval metadata.